The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their exclusivity periods.

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals, the British drugmaker said on Wednesday. Efimosfermin, a monthly subcutaneous injection,

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals’ efimosfermin, a drug ready to hit Phase III trials for the treatment of liver disease.